Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 peptide-pulsed dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
NY-ESO-1 peptide-pulsed dendritic cell vaccine is an investigational cancer immunotherapy consisting of autologous dendritic cells loaded (pulsed) ex vivo with synthetic NY-ESO-1 peptides, commonly the immunodominant 157-165 or longer peptide sequences derived from the NY-ESO-1 cancer-testis antigen. The vaccine aims to stimulate a targeted cellular immune response by enhancing presentation of NY-ESO-1 antigens to patient T cells, inducing NY-ESO-1-specific cytotoxic T lymphocytes (CTLs) and helper T cell responses against NY-ESO-1-positive tumors. The approach is used primarily for solid tumors expressing NY-ESO-1, notably melanoma, sarcoma, and other advanced malignancies. Administration is typically by intradermal or intravenous injection. This approach has been investigated in combination with other immunotherapies such as immune checkpoint inhibitors, α-Galactosylceramide (α-GalCer), and adoptive T cell transfer, in both phase 1 and phase 2 clinical trials. No commercial approval has been granted as of 2025, and trials focus on safety, immunogenicity, and preliminary efficacy[1][3][5][6].
- Other names
- NY-ESO-1 peptide-pulsed DC vaccineNY-ESO1 peptide-pulsed DC vaccineNY-ESO 1 peptide-pulsed DC vaccineNY-ESO-1 long peptide-pulsed DC vaccineNY-ESO1 long peptide-pulsed DC vaccineNY-ESO 1 long peptide-pulsed DC vaccineDCV (NY-ESO-1)NY-ESO-1-pulsed dendritic cell vaccineNY-ESO1-pulsed dendritic cell vaccineNY-ESO 1-pulsed dendritic cell vaccine
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on NY-ESO-1 peptide-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 peptide-pulsed dendritic cell vaccine.